NCT06246149 2026-03-04
ATOM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT07276386 2025-12-11
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05315258 2025-07-17
TebeMRD
University of Oxford
Phase 2 Active not recruiting
NCT02570308 2023-03-21
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
Phase 1/2 Completed
NCT04960891 2022-01-21
Non Applicable
Immunocore Ltd
Available